On Demand 2024 Saturday PM General Sessions

This collection covers general sessions from Saturday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Hit the Ground Running With Billing and Coding
  • Hot Topics and Practical Pearls in Management and Treatment of Skin Diseases
  • Editor's Pick: Best Articles from Annals of Allergy, Asthma and Immunology
  • Anaphylaxis Practice Parameters: Highlights of 2023 Update
  • The Latest Parameters in Allergic Skin Diseases
  • The Community and Academic Allergists Partnership in Education and Research (CAAPER)
  • Biologics for Asthma: Wicked Good Choices

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 10.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Identify basic ICD-10 codes, CPT (E&M and allergy procedure) codes, and HCPCS frequently used allergy codes.
  • Select proper coding and documentation through scenarios and code-it practice.
  • Indicate how proper billing and coding impact practice revenues and revenue cycles.
  • Examine the scientific evidence for the use of integrative medicine therapies in the management of allergic skin diseases. Evaluate topical and oral JAK inhibitors, including risks/benefits for atopic dermatitis.
  • Discover clinical pearls and treatment of prurigo nodularis. Identify allergic conditions in skin of color.
  • Differentiate bullous pemphigoid and pemphigus vulgaris. Assess mast cell disease presentations of the skin. Summarize the physical differences between psoriasis and atopic dermatitis.
  • Identify the best articles in the last year in Annals as determined by the journal editors.
  • Understand why these articles were felt to be the best by the Annals' editors.
  • Describe the diagnostic evaluation of mast cell conditions, including utility of serum tryptase measurement.
  • Apply new evidence to shared decision-making for using certain medications in patients at risk for anaphylaxis.
  • Compare the indications and the emerging new options for prescribing and using epinephrine.
  • Understand ongoing guideline updates for atopic dermatitis.
  • Consider the risks and benefits of diagnostic testing for chronic spontaneous urticaria.
  • Evaluate available evidence for therapeutic agents beyond H1 antihistamines for the treatment of chronic spontaneous urticaria.
  • Simplify the immune pathways of endotypes/biomarkers and correlate their clinical relevance to patients with asthma.
  • Develop asthma treatment algorithms using biomarkers and other tests and decide how to select a biologic and when to switch.
  • Consider novel biomarkers and other ways to assess asthma risk and control in patients currently treated with or being considered for treatment with a biologic.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 10.75 AMA PRA Category 1 Credit™
  • 10.75 Attendance
  • 10.75 CBRN
Course opens: 
11/11/2024
Course expires: 
11/10/2027
Part of: 
On Demand ACAAI 2024 Annual Scientific Meeting General Sessions
Rating: 
0

Madeleine S Ramos, MD, FACAAI
Jonathan A. Olsen, DO, FACAAI
Steven J. Weiss, MD, PhD, FACAAI
M. Razi Rafeeq, MD, FACAAI
Andrew Nickels, MD, FACAAI
Ellen R. Sher, MD, FACAAI
Theresa A. Bingemann, MD, FACAAI
Anil Nanda, MD, FACAAI
Gisoo Ghaffari, MD, FACAAI
Kelly M. Maples, MD, FACAAI
Ama Alexis, MD, FACAAI
Aaron M. Ver Heul, MD, PhD
Julia Cronin, MD, FACAAI
Timothy J. Craig, DO, FACAAI
Mitchell H. Grayson, MD, FACAAI
John J. Oppenheimer, MD, FACAAI
Jonathan M. Spergel, MD, PhD, FACAAI
David R. Stukus, MD, FACAAI
Lara M. Gross, MD
Michael Pistiner, MD MMSc, FACAAI
David B K Golden, MD, FACAAI
Dennis K. Ledford, MD, FACAAI
Susan Waserman, MD, FACAAI
Jay A. Lieberman, MD, FACAAI
Catherine Hammond, MD
Lynda C. Schneider, MD, FACAAI
Jonathan A. Bernstein, MD, FACAAI
Sarbjit Singh Saini, MD
Gailen D. Marshall, Jr, MD, PhD, FACAAI
Jeremy S. Katcher, MD, FACAAI
Maeve E. O'Connor, MD, FACAAI
J. Wesley Sublett, MD, MPH, FACAAI
Kathleen R. May, MD, FACAAI
William E Berger, MD, MBA, FACAAI
Mauli B. Desai, MD, FACAAI
Mario Castro, MD, MPH
Ioana O. Agache, MD

Available Credit

  • 10.75 AMA PRA Category 1 Credit™
  • 10.75 Attendance
  • 10.75 CBRN
Please login or create an account to take this course.